Refine your search
8 trials found for Mieloma
Recruiting
Not yet recruiting
4 trials recruiting
1 trial not yet recruiting
MagnetisMM Clinical Trials
These studies will evaluate the safety and effectiveness of a study medicine, called elranatamab, in people with multiple myeloma.
Recruiting
NCT05317416
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Multiple Myeloma
Male or Female
18+ years
223study location(s)
Recruiting
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Male or Female
18+ years
234study location(s)
Recruiting
NCT05675449
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
Male or Female
18+ years
32study location(s)
Recruiting
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Male or Female
18+ years
66study location(s)
Recruiting
NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Male or Female
18+ years
35study location(s)
Recruiting
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Male or Female
18+ years
238study location(s)
Recruiting
NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Male or Female
18+ years
19study location(s)
Recruiting
NCT05742217
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Male or Female
18+ years
1study location(s)
Saved trials
Saved trials
You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.
Recruiting
Not yet recruiting
Contact us
For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.